GLUCAGON KIT

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

GLUCAGON (RECOMBINANT DNA ORIGIN)

제공처:

ELI LILLY CANADA INC

ATC 코드:

H04AA01

INN (국제 이름):

GLUCAGON

복용량:

1MG

약제 형태:

KIT

구성:

GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG

관리 경로:

INTRAMUSCULAR

패키지 단위:

1 ML

처방전 유형:

Schedule D

치료 영역:

GLYCOGENOLYTIC AGENTS

제품 요약:

Active ingredient group (AIG) number: 0142861001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2023-12-18

제품 특성 요약

GLUCACON (rDNA Origin) Product Monograph
Page 1 of 32
PRODUCT MONOGRAPH
GLUCAGON
GLUCAGON FOR INJECTION, RDNA ORIGIN
1 MG GLUCAGON PER VIAL
Sterile Lyophilized Powder and Diluent
Hyperglycemic Agent
©
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario
M1N 2E8
1-888-545-5972
Date of Approval:
July 9, 2012
www.lilly.ca
Submission Control No: 139332
GLUCACON (rDNA Origin) Product Monograph
Page 2 of 32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTION
............................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...........................................................................................................